Lilly and AstraZeneca gang up on Merck in Alzheimer's
This article was originally published in Scrip
Eli Lilly is to pay AstraZeneca up to $500m in development and regulatory milestone payments, the first $50m of which could be due in the first half of 2015, under a new deal to jointly develop and commercialize AstraZeneca's AZD3293. The oral beta secretase cleaving enzyme (BACE) inhibitor is currently in early clinical development as a potential treatment for Alzheimer's disease.
You may also be interested in...
Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.